Table 2. Characteristics of all the studies included in the meta-analysis.
| Reference, year | Country | Ethnicity | Age* | No.Sample | Design | Stage | Histology | Treatment | Cut-off | NOS | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alagappan M 2016 | Asari S 2016 | Bhatti I 2010 | Inoue D 2015 | Kishi T 2015 | Lee J M 2016 | Liu Z 2016 | Martin H L 2014 | Qi Q 2015 | Shirai Y 2015 | Smith R A 2009 | Tao L 2016 | Wang D S 2012 | Watanabe J 2016 |
| USA | Japan | UK | Japan | Japan | Korea | China | Australia | China | Japan | UK | China | China | Japan |
| Caucasian | Asian | Caucasian | Asian | Asian | Asian | Asian | Australoid | Asian | Asian | Caucasian | Asian | Asian | Asian |
| 75.2(65.9–86.1) | 68(60.3–73) | 65(51–79) | 67(32–88) | 65 (35–85) | 63.5 ± 10.7 | 61(34–83) | 68.5 (35–90) | 61.2 ± 10.7 | 66.5 ± 10.2 | 67 (61–73) | 63.4(23–86) | NR | 67(32–88) |
| 208 | 37 | 84 | 440 | 65 | 82 | 386 | 124 | 211 | 131 | 110 | 159 | 177 | 46 |
| Retrospective | Retrospective | Retrospective | Retrospective | Retrospective | Retrospective | Retrospective | Retrospective | Retrospective | Retrospective | Retrospective | Retrospective | Retrospective | Retrospective |
| III/IV | I-II | NR | I-IV | III/IV | III/IV | I-IV | III/IV | III/IV | I-II | I-II | NR | Ib-IV | Ia-IIb |
| PDAC | PDAC | PDAC | PDAC | PC | PDAC | PDAC | PC | PDAC | PDAC | PDAC | PDAC | PDAC | PDAC |
| R/C | O/C | O/C | O/C/P | CR | C | NR | R /C/P | C | O | O/C | O | O/C/R | O/C O/C |
| 200 | 225 | 200 | 150 | 150 | 150 | 165.5 | 200 | 126 | 150 | 300 | 130.96 | 300 | 200 |
| 6 | 8 | 9 | 7 | 8 | 7 | 7 | 7 | 6 | 7 | 8 | 7 | 8 | 7 |
*values are mean(s.d.) or mean range or median (range) or median(interquartile range) values without s.d. or range are means.
C = chemotherapy, O = operation, R = radiotherapy, P = palliative care, HR = hazard ratio, PLR = platelet-to-lymphocyte ratio, PDAC = pancreatic ductal adenocarcinoma, PC= pancreatic cancer, OS = overall survival, NOS = Newcastle-Ottawa Scale, NR = not reported.